J. Zhan

发表

Listeria monocytogenes personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens

J. Johnston, J. DeVoss, J. Lesch, 2020, bioRxiv.

Local Delivery of OncoVEX Generates SystemicAntitumor ImmuneResponsesEnhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade

R. Ponce, Tiep Le, Achim K. Moesta, 2017 .

Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

E. Lobenhofer, Kristin L. Andrews, B. Herberich, 2015, ACS medicinal chemistry letters.

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

E. Lobenhofer, M. Friedrich, T. Raum, 2020, Clinical Cancer Research.

Novel anti-c-Mpl monoclonal antibodies identified multiple differentially glycosylated human c-Mpl proteins in megakaryocytic cells but not in human solid tumors.

P. Wei, A. Ellison, S. Scully, 2013, Monoclonal antibodies in immunodiagnosis and immunotherapy.

Triazolone/alginate-zinc (II)-montmorillonite sustained release system with improved adsorption capacity and pH-sensitivity

Hongjun Zhou, Huayao Chen, H. Xu, 2020, SN Applied Sciences.

Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade

R. Ponce, Charles Glaus, Tiep Le, 2017, Clinical Cancer Research.

OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models

J. DeVoss, J. Werner, J. Estrada, 2023, Journal for ImmunoTherapy of Cancer.

P15.01 AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer

J. Canon, J. Werner, J. Bailis, 2021 .

Generation and characterization of monoclonal antibodies to human keratinocyte growth factor receptor.

P. Wei, T. Boone, D. Chang, 2006, Hybridoma.

Tumor-specific intravenous gene delivery using oncolytic adenoviruses

Annie Shen, L. Post, S. Laquerre, 2005, Cancer Gene Therapy.

Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

E. Lobenhofer, B. Herberich, A. Tasker, 2015, ACS Medicinal Chemistry Letters.